Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A rare disease breakthrough just landed. The FDA has approved adrabetadex (Lembaz) — the first therapy ever shown to extend survival in children with infantile-onset Niemann-Pick disease type C (NPC). Delivered via intrathecal injection every two weeks, it cut the risk of death by 55% compared to matched controls, raising median survival from 4.9 to 8.5 years in a disease that often proves fatal before age 6.
A rare disease milestone. The FDA has approved adrabetadex (Lembaz; Beren Therapeutics) for adult and pediatric patients (≥7 kg) with infantile-onset Niemann-Pick disease type C (I-NPC) — a rare, fatal lysosomal storage disorder that traps cholesterol in the brain. It's the first NPC therapy ever shown to reduce mortality, marking a significant step forward for a disease with a mean age of death as young as 5.6 years in its earliest-onset form.
How it works. Adrabetadex is a cyclodextrin-based compound that mobilizes cholesterol trapped within neurons, compensating for defective NPC1/NPC2 protein function. Because it cannot cross the blood-brain barrier on its own, it is delivered directly into the spinal fluid every two weeks by a trained provider. Approval was supported by data from 36 treated patients across clinical studies and an expanded access program, compared against matched external controls.
By the Numbers:
Why it matters: Prior NPC therapies — arimoclomol and levacetylleucine — carry age and weight restrictions and have not been shown to reduce mortality, leaving the youngest and most severely affected patients with limited options. Adrabetadex fills that critical gap, offering children with this devastating disease a meaningful chance at more time.